Rapid Serological Test for COVID-19, One-Step-COVID-2019: Accuracy and Implications for Pandemic Control
Authors:
- Luiz Antônio Alves de Menezes-JúniorLMLuiz Antônio Alves de Menezes-Júnior
- Aline Priscila BatistaABAline Priscila Batista
- Luciano Garcia LourençãoLuciano Garcia Lourenção
- Ana Maria Sampaio RochaARAna Maria Sampaio Rocha
- Nara Nunes LageNLNara Nunes Lage
- Keila Furbino BarbosaKBKeila Furbino Barbosa
- George Luiz Lins Machado-CoelhoGeorge Luiz Lins Machado-Coelho
- Adriana Lúcia MeirelesAMAdriana Lúcia Meireles
Open Access
Abstract
Background: Accurate and rapid testing for COVID-19 is critical for effective disease management and control. The One-Step-COVID-2019-Test was developed as a rapid serological test to detect antibodies against SARS-CoV-2. Objective: To estimate the accuracy of the rapid serological test for COVID-19 using One-Step-COVID-2019. Methods: We conducted a population-based serological survey with a stratified sampling of 593 adults between October and December 2020, prior to mass vaccination and during a period of limited availability of rapid tests. Participants provided 7.5 mL of serum, which was tested using the One-Step-COVID-2019-Test for IgM-IgG antibodies without distinction, as well as an in-house ELISA for IgG against the spike protein. Statistical analysis accounted for sampling weights, with accuracy assessed through sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), Youden index, and kappa coefficient, using ELISA as the reference standard. McNemar’s test identified significant differences between the test results. Results: The ELISA-based prevalence of infection was 11.1%. The One-Step-COVID-2019-Test showed low sensitivity (27.0–30.8%) but high specificity (89.9–96.6%), with poor agreement (kappa: 0.290–0.337), particularly among asymptomatic individuals. Conclusions: The One-Step-COVID-2019 rapid test for COVID-19 demonstrated inadequate performance, characterized by low sensitivity and poor reliability, making it unsuitable for effective serological surveillance.Keywords
Funding Information
- Federal University of Ouro Preto (UFOP) (001, 0676/2020, 88881.504995/2020–01, 001/2021, APQ02445–21)
- Brazilian Council for Scientific and Technological Development (CNPq) (001, 0676/2020, 88881.504995/2020–01, 001/2021, APQ02445–21)
- Coordination for the Improvement of Higher Education Personnel-Brazil (CAPES) (001, 0676/2020, 88881.504995/2020–01, 001/2021, APQ02445–21)
- Foundation for Research Support of the State of Minas Gerais (FAPEMIG) (001, 0676/2020, 88881.504995/2020–01, 001/2021, APQ02445–21)
This publication has 16 references indexed in Scilit:
- COVID-Inconfidentes - SARS-CoV-2 seroprevalence in two Brazilian urban areas in the fourth quarter 2020: study protocol and initial resultsPoblación y Salud en Mesoamérica, 2023
- Development and validation of an enzyme-linked immunoassay kit for diagnosis and surveillance of COVID-19Journal of Clinical Virology Plus, 2022
- Viral dynamics and antibody responses in people with asymptomatic SARS-CoV-2 infectionSignal Transduction and Targeted Therapy, 2021
- Rethinking Covid-19 Test Sensitivity — A Strategy for ContainmentNew England Journal of Medicine, 2020
- SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveysThe Lancet Global Health, 2020
- Evaluation of SARS-CoV-2 serology assays reveals a range of test performanceNature Biotechnology, 2020
- Population-based surveys of antibodies against SARS-CoV-2 in Southern BrazilNature Medicine, 2020
- Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysisBMJ, 2020
- Clinical and immunological assessment of asymptomatic SARS-CoV-2 infectionsNature Medicine, 2020
- Diagnostic test evaluation methodology: A systematic review of methods employed to evaluate diagnostic tests in the absence of gold standard – An updatePLOS ONE, 2019